234 related articles for article (PubMed ID: 26629687)
1. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Schneider JS; Seyfried TN; Choi HS; Kidd SK
PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
[TBL] [Abstract][Full Text] [Related]
2. Intracranial V. cholerae sialidase protects against excitotoxic neurodegeneration.
Dhanushkodi A; McDonald MP
PLoS One; 2011; 6(12):e29285. PubMed ID: 22195039
[TBL] [Abstract][Full Text] [Related]
3. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
[TBL] [Abstract][Full Text] [Related]
4. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Schneider JS; Kean A; DiStefano L
J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
[TBL] [Abstract][Full Text] [Related]
5. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
Itokazu Y; Fuchigami T; Morgan JC; Yu RK
Mol Ther; 2021 Oct; 29(10):3059-3071. PubMed ID: 34111562
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
7. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
8. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
9. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
Li Y; Liu W; Li L; Hölscher C
Eur J Pharmacol; 2017 Feb; 797():162-172. PubMed ID: 27913104
[TBL] [Abstract][Full Text] [Related]
10. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
12. The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism.
Schneider JS; Bradbury KA; Anada Y; Inokuchi J; Anderson DW
Brain Res; 2006 Jul; 1099(1):199-205. PubMed ID: 16764837
[TBL] [Abstract][Full Text] [Related]
13. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
Rothblat DS; Schneider JS
Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
[TBL] [Abstract][Full Text] [Related]
14. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
Schneider JS; DiStefano L
Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
[TBL] [Abstract][Full Text] [Related]
15. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
[TBL] [Abstract][Full Text] [Related]
16. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
17. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Schneider JS
J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Chen Y; Zhang Y; Li L; Hölscher C
Eur J Pharmacol; 2015 Dec; 768():21-7. PubMed ID: 26409043
[TBL] [Abstract][Full Text] [Related]
19. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.
Schneider JS
PLoS One; 2018; 13(6):e0199189. PubMed ID: 29902255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
